Fulcrum Therapeutics, Inc. Quarterly Depreciation in USD from Q2 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Fulcrum Therapeutics, Inc. quarterly/annual Depreciation history and growth rate from Q2 2018 to Q3 2024.
  • Fulcrum Therapeutics, Inc. Depreciation for the quarter ending September 30, 2024 was $400K, a 20% decline year-over-year.
  • Fulcrum Therapeutics, Inc. Depreciation for the twelve months ending September 30, 2024 was $1.79M, a 20.5% decline year-over-year.
  • Fulcrum Therapeutics, Inc. annual Depreciation for 2023 was $2.17M, a 10% decline from 2022.
  • Fulcrum Therapeutics, Inc. annual Depreciation for 2022 was $2.41M, a 4.02% decline from 2021.
  • Fulcrum Therapeutics, Inc. annual Depreciation for 2021 was $2.52M, a 5.72% increase from 2020.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $1.79M $400K -$100K -20% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $1.89M $400K -$200K -33.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-31
Q1 2024 $2.09M $479K -$87K -15.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 $2.17M $506K -$72K -12.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 $2.24M $500K -$100K -16.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $2.34M $600K -$100K -14.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-31
Q1 2023 $2.44M $566K +$30K +5.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 $2.41M $578K -$34K -5.56% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 $2.45M $600K $0 0% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $2.45M $700K $0 0% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $2.45M $536K -$67K -11.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $2.52M $612K -$128K -17.3% Oct 1, 2021 Dec 31, 2021 10-K/A 2023-06-26
Q3 2021 $2.64M $600K +$100K +20% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $2.54M $700K +$100K +16.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $2.44M $603K +$64K +11.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $2.38M $740K +$191K +34.8% Oct 1, 2020 Dec 31, 2020 10-K/A 2023-06-26
Q3 2020 $2.19M $500K $0 0% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $2.19M $600K +$100K +20% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 $2.09M $539K +$35K +6.94% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $2.05M $549K Oct 1, 2019 Dec 31, 2019 10-K/A 2023-06-23
Q3 2019 $500K +$100K +25% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 $500K +$300K +150% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 $504K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-13
Q3 2018 $400K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 $200K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.